OPK Stock Risk & Deep Value Analysis
OPKO Health Inc
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About OPK Stock
We analyzed OPKO Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran OPK through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
OPK Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Upcoming Risk Events
- 📅
Slower-than-expected Ngenla adoption or competitive pressures
- 📅
Continued sharp decline in BioReference Labs revenue
- 📅
Failure of pipeline assets in clinical trials
- 📅
Persistent unprofitability leading to renewed cash burn concerns despite current reserves
Unlock OPK Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does OPKO Health Inc (OPK) Do?
Market Cap
$888.10M
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,997
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Visit OPKO Health Inc WebsiteInvestment Thesis
OPKO Health is a deep-value turnaround play hinged on the successful global commercialization of Ngenla/Skytrofa, which offers a clear competitive edge. Despite current revenue headwinds, the company's significantly fortified balance sheet, substantial cash reserves, and commitment to shareholder value through share repurchases provide a crucial runway. This financial stability, combined with a potentially undervalued asset base, offers a speculative opportunity for substantial gains if Ngenla's growth can ultimately reverse the company's overall revenue decline and demonstrate a clear path to profitability.
Is OPK Stock Undervalued?
Unlock the full AI analysis for OPK
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
OPK Price Targets & Strategy
12-Month Target
$2.50
Bull Case
$5.00
Bear Case
$0.80
Valuation Basis
Based on a projected market re-rating to 2.8x FY2026 P/S, reflecting Ngenla's ongoing global launch and strong balance sheet.
Entry Strategy
Consider dollar-cost averaging near current levels ($1.10-$1.20), close to the recent insider purchase price of $1.14.
Exit Strategy
Take partial profits at $2.50, re-evaluate at $4.00, with a stop-loss order placed below $0.95 (recent support).
Portfolio Allocation
2-4% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is OPK Financially Healthy?
Valuation
P/E Ratio
7.46
Profitability
Gross Margin
43.20%
Net Margin
-37.19%
Return on Equity
-17.42%
EPS
$-0.30
Balance Sheet
Cash & Equivalents
$369.10M
Cash Flow
Operating Cash Flow
-$28.20M
Does OPK Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable (Ngenla's moat is solidifying with global launch, but overall company struggles to leverage it for broader growth)
Moat Sources
3 Identified
Ngenla's once-weekly formulation provides a durable advantage in the hGH market, protected by patents and supported by Pfizer's global reach. However, competition in other segments (like lab services) is intense, limiting a company-wide wide moat.
Moat Erosion Risks
- •Emergence of superior long-acting hGH therapies or biosimilars
- •Patent challenges or expiry for Ngenla
- •Failure to convert Ngenla's clinical advantage into significant market adoption
OPK Competitive Moat Analysis
Sign up to see competitive advantages
OPK Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data available, but typically speculative retail interest around growth catalysts)
Institutional Sentiment
Neutral/Slightly Negative (Consensus 'Hold' from 6 firms, recent target cuts by Barrington Research and Wall Street Zen, but high institutional ownership at 64.63%)
Insider Activity (Form 4)
Director John Paganelli bought 10,000 shares for $11,400 on March 20, 2026 (avg $1.14/share); post-purchase ownership 394,340 shares (+2.6%). No CEO/CFO activity reported.
Options Flow
Normal options activity (no specific unusual activity provided)
Earnings Intelligence
Next Earnings
2026-04-29 (Estimated Q1 2026)
Surprise Probability
Medium (Q4 2025 EPS beat consensus, but revenue guidance is lower, increasing scrutiny)
Historical Earnings Pattern
No consistent historical pattern of stock price reaction to earnings reports provided in the data.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no specific peer provided in research; relevant competitors vary by segment, e.g., Novo Nordisk for hGH, Quest Diagnostics for lab services)
Market Share Trend
Gaining in the hGH segment with Ngenla/Skytrofa, but likely losing overall market share due to declining consolidated revenue, suggesting weakness in other business units.
Valuation vs Peers
Trading at a discount on EV/Sales (approx. 0.9x based on FY26 guidance) relative to many specialty pharma/biotech firms, largely due to current revenue contraction and unprofitability.
Competitive Advantages
- •Ngenla's differentiated once-weekly dosing (significant convenience advantage)
- •Strategic global partnership with Pfizer for Ngenla distribution
- •Proprietary technology and intellectual property (IP) for pipeline assets
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive OPK Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated April 29, 2026)
- •Updates on Ngenla/Skytrofa global market penetration and sales growth
Medium-Term (6-18 months)
- •Potential Regeneron milestones (>$200M)
- •Advancements and updates on ModeX Therapeutics pipeline assets
- •Stabilization and potential return to growth in BioReference Labs segment
Long-Term (18+ months)
- •Ngenla/Skytrofa achieving significant market leadership in the long-acting hGH segment
- •Successful commercialization of additional pipeline products
- •Strategic partnerships expanding product reach or reducing R&D costs
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for OPK?
- ✓
Accelerated growth in Ngenla/Skytrofa sales exceeding expectations
- ✓
Evidence of stabilization or growth in the BioReference Labs segment
- ✓
Clear path to consolidated profitability and positive free cash flow
Bull Case Analysis
See what could go right with Premium
Competing with OPK
See how OPKO Health Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
OPKO Health Inc OPK | $888.1M | 5.5 | 7.5 | $863.5M | -37.2% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for OPKO Health Inc (OPK)?
As of March 24, 2026, OPKO Health Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of OPKO Health Inc?
OPKO Health Inc's market capitalization is approximately $888.1M. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does OPKO Health Inc use?
OPK is the ticker symbol for OPKO Health Inc. The company trades on the NMS.
What is the risk level for OPK stock?
Our analysis rates OPKO Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of OPK?
OPKO Health Inc currently has a price-to-earnings (P/E) ratio of 7.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is OPKO Health Inc's revenue growing?
OPKO Health Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is OPK stock profitable?
OPKO Health Inc has a profit margin of -37.2%. The company is currently unprofitable.
How often is the OPK DVR analysis updated?
Our AI-powered analysis of OPKO Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for OPK (OPKO Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.